Combined Use of Pharmaceutical Agents
A combination of anti-glaucoma drugs is often required to achieve the target intraocular pressure when treating glaucoma. The efficacy and safety of combining these drugs are discussed in the first part of this chapter. Since patients with glaucoma also often suffer from systemic illnesses, such as hypertension, cardiovascular disease, and respiratory diseases, we also discuss the potential problems associated with glaucoma medications and systemic therapies for these conditions in this chapter. Elevated intraocular pressure or glaucoma can occur following many ophthalmic therapeutic procedures. How to identify and treat this type of glaucoma is discussed. Finally, combined uses of systemic and topical agents to control higher IOP are briefly discussed at the end of the chapter.
KeywordsAnti-glaucoma drugs Combined use Systemic disease Triamcinolone acetonide Dexamethasone intravitreal implant Systemic agents
- 3.Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8(1):24–30.CrossRefGoogle Scholar
- 38.Francois J. The importance of the mucopolysaccharides in intraocular pressure regulation. Investig Ophthalmol. 1975;14(3):173–6.Google Scholar